A multicentre, observational study analysing treatment patterns and outcomes of newly diagnosed Acute Myeloid Leukemia patients receiving Venetoclax Combinations vs Other Therapies

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Azacitidine (Primary) ; Decitabine (Primary) ; Venetoclax (Primary) ; Cytarabine; Cytarabine/daunorubicin
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

13 Dec 2022 Interim Results( n=468, from May 2022 ) assessing Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies presented at the 64th American Society of Hematology Annual Meeting and Exposition
14 Dec 2021 Results (n=266) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
17 Jul 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com